SCHEMBL3582211

SCHEMBL3582211

COc1ccc(CC2CCN(C(=O)OC(C)(C)C)CC2)c(N)c1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.55
ALDH1A1 P00352 1/20 0.53
BACE1 P56817 2/20 0.52
STS P08842 2/20 0.51
CTSD P07339 1/20 0.49
CTSE P14091 1/20 0.49
TGFBR1 P36897 2/20 0.48
HTT P42858 1/20 0.48
GPR119 Q8TDV5 7/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RYR2 Q92736 1/20 0.47
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20971864 0.88 EPHX2 (0.56) EPHX2ALDH1A1BACE1STSTGFBR1
SCHEMBL5214882 0.87 EPHX2 (0.57) EPHX2ALDH1A1BACE1STSTGFBR1
SCHEMBL3587135 0.86 PIK3CG (0.52) BACE1MEN1KMT2ARYR2
SCHEMBL5204514 0.84 HTR1A (0.55) EPHX2ALDH1A1STSTGFBR1
SCHEMBL28169019 0.81 ALDH1A1 (0.62) ALDH1A1BACE1STSCTSDCTSE
SCHEMBL18280123 0.81 ALDH1A1 (0.54) EPHX2ALDH1A1BACE1STSTGFBR1
SCHEMBL8602574 0.80 TGFBR1 (0.54) EPHX2ALDH1A1STSTGFBR1GPR119
SCHEMBL16825188 0.80 TGFBR1 (0.56) EPHX2ALDH1A1STSTGFBR1MEN1
SCHEMBL6412710 0.79 HTR1A (0.50) EPHX2ALDH1A1STSTGFBR1
SCHEMBL18280003 0.79 ALDH1A1 (0.52) EPHX2ALDH1A1BACE1STSTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 EPHX2 3222/4885ALDH1A1 577/4885BACE1 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.